Interestingly, a recent work suggested an unexpected use of DOT1L as an indicator of eligibility for immunotherapy, as its expression level has been reported to mark immune-activated breast cancers (Noblejas-López et al., 2019). This evidence concerns the gene DOT1L and breast carcinoma.